COMPANY PROFILE

Ingenix.ai

Explore full profile

Biological reasoning engine for clinical R&D

Warsaw, PolandFounded 2023Biotech & Life Sciences

Valuation $50–100M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Ingenix.ai

Ingenix.ai is a Warsaw AI-biology company founded in 2023 that builds a Biological Reasoning Engine for translational and clinical R&D decisions in biotech and pharma. Its Modality Fusion architecture integrates best-in-class models across biological scales and data types—omics, literature, imaging, pathways and clinical data—then reasons across their representations, returning every prediction with a stepwise trace of mechanism, evidence and caveats. The founding team includes AI researchers from Applica (acquired by Snowflake in 2022; TILT model contributed to GPT-4 benchmarks) and senior pharma scientists; go-to-market is partner engagement via a Qualified Access Program rather than self-serve model installs. In June 2026 Ingenix raised a €13 million seed-extension led by Sofinnova Partners, with Inovo VC and OTB VC, to scale the Engine and broaden pharma/biotech partnerships. Sources: Sofinnova Partners 3 Jun 2026; PR Newswire; ingenix.ai.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2023
Headquarters: Warsaw, Poland
Employees: 39
Open positions: None listed
Dealroom signal: 91.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Drug Development, Core AI, Clinical Trials, genAI Applications, Techbio, CompBio, Techbio Drug Discovery
Technology: Artificial Intelligence, Deep Tech
Business model: SaaS
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SEED✓Equity / VC	Jun 2026	$14M	$57M	Inovo.vc · OTB Ventures · Sofinnova Partners	↗
SEED✓Equity / VC	Apr 2025	$9.9M	$40M	International Finance Corporation · OTB Ventures · Inovo.vc	↗

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Ingenix.ai website traffic

Latest recorded traffic for Ingenix.ai is 2.9K monthly website visits, up 900% over the last three months. Ingenix.ai's team grew 290% over the past year.

Latest monthly visits2.9K 3-month web change+900% 1-year team growth+290%

Monthly website visitsApr 2025–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
OWOwkinCollaborative research platform and unique AI drug development solutions that make precision medicine a reality	Paris, France	Operational	425	$368M	$1B
OMOmniscopeAI-powered immune databank for diagnostics and therapeutics	Barcelona, Spain	Operational
AQAqemiaUsing quantum-physics with AI to speed up the discovery of novel drug molecules	Paris, France	Operational
BIBioptimusUniversal AI foundation models for biological research	Paris, France	Operational
LLLatent LabsWe are making biology programmable to transform health and sustainability for the benefit of all	London, United Kingdom	Operational
ALALLOXHarnessing the power of genetics and AI to learn the biophysical parameters governing protein function	Barcelona, Spain	Operational
ILIgnota LabsUsing cutting-edge AI algorithms to predict toxic endpoints, earlier in the drug discovery process	London, United Kingdom	Operational
CRCradleAI-powered protein design and engineering platform.	Amsterdam, Netherlands	Operational